ArticleScientific reports2026
Distinct media requirements for dopaminergic neuron reprogramming from human glia and fibroblasts.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct reprogramming of somatic cells into induced dopaminergic neurons (iDANs) is a promising strategy for replacing degenerated dopamine neurons in Parkinson's disease. One current bottleneck for translation of direct neuronal reprogramming is the low reprogramming efficiency and difficulty to acquire enough tyrosine hydroxylase (TH) positive iDANs. Here we systematically refine the culture conditions used for dopaminergic reprogramming of human stem cell-derived glial progenitor cells (GPCs) and adult dermal fibroblasts (DFs). Starting from a standard reprogramming medium containing base medium, growth factors and small molecules, we systematically compared three base media and removed individual small molecules to determine their specific contribution to reprogramming outcome. The GPCs and DFs were reprogrammed using established transcription factor-based strategies combined with REST inhibition. We found that the two starting cell types benefited from different culture conditions. For GPCs, B27/Neurobasal medium without small molecules yielded the highest neuronal and TH reprogramming efficiency, whereas DFs yielded the highest efficiencies in N2/DMEM/Neurobasal containing small molecules. Further characterization of the GPC-derived iDANs showed that these cells were functional, expressed key dopaminergic markers, and released dopamine upon stimulation. Together, these findings demonstrate that media composition is a key parameter influencing dopaminergic reprogramming efficiency across starting cell types in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.